Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275004 | 0.85 | CYP1A2 (0.48) | CYP1A2PDE10AMEN1KMT2A | |
| SCHEMBL4271009 | 0.83 | CYP1A2 (0.40) | CYP1A2SQORMEN1KMT2A | |
| SCHEMBL16796101 | 0.79 | CYP1A2 (0.53) | CYP1A2PDE10ASQORMEN1KMT2A | |
| SCHEMBL11916226 | 0.79 | CYP2C19 (0.42) | CYP1A2PDE10ASQORMEN1KMT2A | |
| SCHEMBL1444957 | 0.76 | ALDH1A1 (0.38) | CYP1A2SQORMEN1KMT2A | |
| SCHEMBL11059135 | 0.76 | CCNA2 (0.46) | CYP1A2PDE10A | |
| SCHEMBL10268454 | 0.76 | CYP1A2 (0.50) | CYP1A2PDE10A | |
| SCHEMBL501178 | 0.76 | CYP1A2 (0.50) | CYP1A2PDE10A | |
| SCHEMBL10604745 | 0.73 | CCNA2 (0.34) | CYP1A2SQOR | |
| SCHEMBL501295 | 0.72 | CYP1A2 (0.47) | CYP1A2PDE10AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20060223708-A1 | Substituted N-[pyrimidin-2-ylmethyl]carboxamides and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | CYP1A2 2358/4885PDE10A 2180/4885SQOR 1871/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | CYP1A2 2358/4885PDE10A 2180/4885SQOR 1871/4885 |
| US-20060223708-A1 | Substituted N-[pyrimidin-2-ylmethyl]carboxamides and their use as herbicides and plant growth regulators | CNPY2, PRXL2A, CBR3 | CYP1A2 225/4885PDE10A 2598/4885SQOR 170/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | CYP1A2 2358/4885PDE10A 2180/4885SQOR 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.